Imeglimin, a novel antidiabetic agent related to metformin, attenuates knee osteoarthritis development and progression through AMPK activation and NF-κB signaling inhibition
Imeglimin enhances protective functions in joint tissue cells and alleviates experimental OA in preclinical mouse models, supporting its potential as a therapeutic candidate for knee OA.
Authors
- Masanari Kuwahara (ORCID: https://orcid.org/0000-0002-8621-4629)
- Ichiro Kurakazu (ORCID: https://orcid.org/0000-0002-2254-6536)
- Koki Kato (ORCID: https://orcid.org/0000-0003-2562-1893)
- Taisuke Uchida (ORCID: https://orcid.org/0000-0003-4511-4901)
- Takumi Kita
- Ryota Hirose
- Yuki Hyodo
- Yukio Akasaki (ORCID: https://orcid.org/0000-0002-3666-3952)
- Yasuharu Nakashima
- Mamiko Sakai
Institutions
- Kyushu University (JP)
- Kyushu University Hospital (JP)
- Kyushu International University (JP)
Publication Details
- Journal
- Osteoarthritis and Cartilage
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1016/j.joca.2025.11.007
- Primary Topic
- Metabolism, Diabetes, and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Society for the Promotion of Science